Loading...
In the prior industry-sponsored, randomized, open-label, phase III PROfound study, progression-free survival (PFS) was longer with the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib than with abiraterone or enzalutamide in men who had metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM alterations (NEJM JW Oncol Hematol Jun 2020 and N Engl J Med 2020; 382:2091). The authors now report final overall survival (OS) data.
Patients were placed into two cohorts: cohort A (245 patients) had alterations in BRCA1, BRCA2, or ATM, and cohort B (142 patients) had alterations in any of 12 other prespecified genes that have a role in homologous recombination repair. Patients in each cohort were random…